STOCK TITAN

[SCHEDULE 13G/A] GH Research PLC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

RA Capital and related persons report a 12.4% stake in GH Research PLC as of June 30, 2025. The filing shows aggregate ownership of 7,676,697 Ordinary Shares out of 62,028,145 outstanding, based on the issuer's February 15, 2025 filing. The RA Capital Healthcare Fund directly holds 7,485,080 shares (12.1%) and RA Capital Nexus Fund II holds 191,617 shares. Reported holdings reflect shared voting and shared dispositive power only; sole voting and dispositive power are zero. The filing states RA Capital serves as investment adviser and has sole power to vote and dispose of the funds’ reported shares, while the funds disclaim beneficial ownership for purposes of Section 13(d) because they delegated those powers and may not revoke that delegation on less than 61 days’ notice.

RA Capital e soggetti correlati dichiarano una partecipazione del 12,4% in GH Research PLC al 30 giugno 2025. La comunicazione indica una detenzione complessiva di 7.676.697 azioni ordinarie su 62.028.145 in circolazione, basandosi sul deposito dell'emittente del 15 febbraio 2025. RA Capital Healthcare Fund detiene direttamente 7.485.080 azioni (12,1%) e RA Capital Nexus Fund II possiede 191.617 azioni. Le partecipazioni riportate riguardano esclusivamente potere di voto congiunto e potere dispositvo congiunto; il potere di voto e dispositvo esclusivo è pari a zero. Nel deposito si precisa che RA Capital agisce come consulente d'investimento e detiene il potere esclusivo di votare e disporre delle azioni segnalate dei fondi, mentre i fondi negano la titolarità effettiva ai fini della Sezione 13(d) perché hanno delegato tali poteri e non possono revocare la delega con un preavviso inferiore a 61 giorni.

RA Capital y personas relacionadas informan una participación del 12,4% en GH Research PLC al 30 de junio de 2025. La presentación muestra una propiedad agregada de 7.676.697 acciones ordinarias de un total de 62.028.145 en circulación, basada en el documento del emisor del 15 de febrero de 2025. RA Capital Healthcare Fund posee directamente 7.485.080 acciones (12,1%) y RA Capital Nexus Fund II tiene 191.617 acciones. Las tenencias reportadas reflejan exclusivamente poder de voto compartido y poder dispositvo compartido; el poder de voto y dispositvo exclusivo es cero. En la presentación se indica que RA Capital actúa como asesor de inversiones y tiene el poder exclusivo para votar y disponer de las acciones reportadas de los fondos, mientras que los fondos renuncian a la condición de beneficiarios a efectos de la Sección 13(d) porque delegaron esos poderes y no pueden revocar esa delegación con menos de 61 días de preaviso.

RA Capital 및 관련자는 2025년 6월 30일 기준으로 GH Research PLC 지분 12.4%를 신고했습니다. 제출서류에 따르면 발행주식수 62,028,145주 중 총 7,676,697 보통주를 보유하고 있으며, 이는 발행사의 2025년 2월 15일 제출자료를 기준으로 합니다. RA Capital Healthcare Fund는 직접 7,485,080주(12.1%)를 보유하고 있고 RA Capital Nexus Fund II는 191,617주를 보유하고 있습니다. 신고된 보유는 공동 의결권 및 공동 처분권만을 반영하며, 단독 의결권 및 단독 처분권은 0입니다. 제출서류에는 RA Capital이 투자자문사로서 해당 펀드의 신고된 주식을 단독으로 의결·처분할 권한을 보유한다고 되어 있으며, 펀드들은 이러한 권한을 위임했기 때문에 섹션 13(d) 상의 실소유자 지위를 부인한다고 명시되어 있으며 위임 해지는 61일 미만의 통지로는 불가능합니다.

RA Capital et des personnes liées déclarent une participation de 12,4 % dans GH Research PLC au 30 juin 2025. Le dépôt indique une détention globale de 7 676 697 actions ordinaires sur 62 028 145 en circulation, basée sur le dossier de l'émetteur du 15 février 2025. RA Capital Healthcare Fund détient directement 7 485 080 actions (12,1 %) et RA Capital Nexus Fund II détient 191 617 actions. Les participations déclarées reflètent uniquement le pouvoir de vote partagé et le pouvoir de disposition partagé ; le pouvoir de vote et de disposition exclusif est nul. Le dépôt précise que RA Capital agit en tant que conseiller en investissement et a le pouvoir exclusif de voter et de disposer des actions déclarées des fonds, tandis que les fonds déclinent la qualité de bénéficiaire au titre de la Section 13(d) car ils ont délégué ces pouvoirs et ne peuvent pas révoquer cette délégation avec un préavis inférieur à 61 jours.

RA Capital und verbundene Personen melden zum 30. Juni 2025 einen Anteil von 12,4% an GH Research PLC. Die Meldung weist ein Aggregat von 7.676.697 Stammaktien von insgesamt 62.028.145 aus, basierend auf der Meldung des Emittenten vom 15. Februar 2025. Der RA Capital Healthcare Fund hält direkt 7.485.080 Aktien (12,1%) und der RA Capital Nexus Fund II 191.617 Aktien. Die gemeldeten Bestände spiegeln nur gemeinsames Stimmrecht und gemeinsames Verfügungsrecht wider; alleiniges Stimm- und Verfügungsrecht beträgt null. In der Meldung heißt es, RA Capital fungiere als Investmentberater und habe die alleinige Befugnis, über die gemeldeten Fondsanteile abzustimmen und zu verfügen, während die Fonds aufgrund der Delegation dieser Befugnisse im Sinne von Abschnitt 13(d) den wirtschaftlichen Eigentumsvorbehalt ablehnen und diese Delegation nicht mit weniger als 61 Tagen Frist widerrufen können.

Positive
  • Significant institutional ownership disclosed (12.4%), providing transparent investor information
  • Use of Schedule 13G/A indicates the reporting persons represent a passive stake rather than an intent to control
Negative
  • Double-digit stake (12.4%) is material and could concern other shareholders despite passive filing
  • Shared voting/dispositive power with adviser delegation concentrates decision authority even though funds disclaim beneficial ownership

Insights

TL;DR: RA Capital reports a material passive stake in GH Research (12.4%) with shared control via adviser delegation.

RA Capital and affiliated funds hold a significant minority position representing 12.4% of GHRS ordinary shares, disclosed on a Schedule 13G/A rather than a 13D, indicating the holders state no intent to influence control. The structure shows the Fund holds the bulk of the position and has delegated sole voting and dispositive authority to RA Capital, while the funds disclaim beneficial ownership for 13(d) purposes because the delegation cannot be revoked in under 61 days. This is a typical institutional passive reporting arrangement but is material given the double-digit stake, which could attract investor attention.

TL;DR: Shared voting power and adviser control create governance relevance without admission of control intent.

The filing discloses shared voting power of 7,676,697 shares and zero sole power, which indicates coordinated authority across reporting persons. The explicit disclaimer of 'group' status and the assertion that the funds disavow beneficial ownership for Section 13(d) purposes reflect legal positioning to avoid control-stake obligations. For governance, a 12.4% stake is meaningful: while filed as passive, the adviser’s delegation of sole authority to vote could concentrate influence operationally, even if the signatories deny intent to change control.

RA Capital e soggetti correlati dichiarano una partecipazione del 12,4% in GH Research PLC al 30 giugno 2025. La comunicazione indica una detenzione complessiva di 7.676.697 azioni ordinarie su 62.028.145 in circolazione, basandosi sul deposito dell'emittente del 15 febbraio 2025. RA Capital Healthcare Fund detiene direttamente 7.485.080 azioni (12,1%) e RA Capital Nexus Fund II possiede 191.617 azioni. Le partecipazioni riportate riguardano esclusivamente potere di voto congiunto e potere dispositvo congiunto; il potere di voto e dispositvo esclusivo è pari a zero. Nel deposito si precisa che RA Capital agisce come consulente d'investimento e detiene il potere esclusivo di votare e disporre delle azioni segnalate dei fondi, mentre i fondi negano la titolarità effettiva ai fini della Sezione 13(d) perché hanno delegato tali poteri e non possono revocare la delega con un preavviso inferiore a 61 giorni.

RA Capital y personas relacionadas informan una participación del 12,4% en GH Research PLC al 30 de junio de 2025. La presentación muestra una propiedad agregada de 7.676.697 acciones ordinarias de un total de 62.028.145 en circulación, basada en el documento del emisor del 15 de febrero de 2025. RA Capital Healthcare Fund posee directamente 7.485.080 acciones (12,1%) y RA Capital Nexus Fund II tiene 191.617 acciones. Las tenencias reportadas reflejan exclusivamente poder de voto compartido y poder dispositvo compartido; el poder de voto y dispositvo exclusivo es cero. En la presentación se indica que RA Capital actúa como asesor de inversiones y tiene el poder exclusivo para votar y disponer de las acciones reportadas de los fondos, mientras que los fondos renuncian a la condición de beneficiarios a efectos de la Sección 13(d) porque delegaron esos poderes y no pueden revocar esa delegación con menos de 61 días de preaviso.

RA Capital 및 관련자는 2025년 6월 30일 기준으로 GH Research PLC 지분 12.4%를 신고했습니다. 제출서류에 따르면 발행주식수 62,028,145주 중 총 7,676,697 보통주를 보유하고 있으며, 이는 발행사의 2025년 2월 15일 제출자료를 기준으로 합니다. RA Capital Healthcare Fund는 직접 7,485,080주(12.1%)를 보유하고 있고 RA Capital Nexus Fund II는 191,617주를 보유하고 있습니다. 신고된 보유는 공동 의결권 및 공동 처분권만을 반영하며, 단독 의결권 및 단독 처분권은 0입니다. 제출서류에는 RA Capital이 투자자문사로서 해당 펀드의 신고된 주식을 단독으로 의결·처분할 권한을 보유한다고 되어 있으며, 펀드들은 이러한 권한을 위임했기 때문에 섹션 13(d) 상의 실소유자 지위를 부인한다고 명시되어 있으며 위임 해지는 61일 미만의 통지로는 불가능합니다.

RA Capital et des personnes liées déclarent une participation de 12,4 % dans GH Research PLC au 30 juin 2025. Le dépôt indique une détention globale de 7 676 697 actions ordinaires sur 62 028 145 en circulation, basée sur le dossier de l'émetteur du 15 février 2025. RA Capital Healthcare Fund détient directement 7 485 080 actions (12,1 %) et RA Capital Nexus Fund II détient 191 617 actions. Les participations déclarées reflètent uniquement le pouvoir de vote partagé et le pouvoir de disposition partagé ; le pouvoir de vote et de disposition exclusif est nul. Le dépôt précise que RA Capital agit en tant que conseiller en investissement et a le pouvoir exclusif de voter et de disposer des actions déclarées des fonds, tandis que les fonds déclinent la qualité de bénéficiaire au titre de la Section 13(d) car ils ont délégué ces pouvoirs et ne peuvent pas révoquer cette délégation avec un préavis inférieur à 61 jours.

RA Capital und verbundene Personen melden zum 30. Juni 2025 einen Anteil von 12,4% an GH Research PLC. Die Meldung weist ein Aggregat von 7.676.697 Stammaktien von insgesamt 62.028.145 aus, basierend auf der Meldung des Emittenten vom 15. Februar 2025. Der RA Capital Healthcare Fund hält direkt 7.485.080 Aktien (12,1%) und der RA Capital Nexus Fund II 191.617 Aktien. Die gemeldeten Bestände spiegeln nur gemeinsames Stimmrecht und gemeinsames Verfügungsrecht wider; alleiniges Stimm- und Verfügungsrecht beträgt null. In der Meldung heißt es, RA Capital fungiere als Investmentberater und habe die alleinige Befugnis, über die gemeldeten Fondsanteile abzustimmen und zu verfügen, während die Fonds aufgrund der Delegation dieser Befugnisse im Sinne von Abschnitt 13(d) den wirtschaftlichen Eigentumsvorbehalt ablehnen und diese Delegation nicht mit weniger als 61 Tagen Frist widerrufen können.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:08/14/2025
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:08/14/2025
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:08/14/2025
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:08/14/2025
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 15, 2025)

FAQ

How many GH Research (GHRS) shares do RA Capital and affiliates report owning?

The filing reports an aggregate of 7,676,697 Ordinary Shares, representing 12.4% of outstanding shares based on 62,028,145 shares.

What portion of the stake is held by RA Capital Healthcare Fund, L.P.?

The RA Capital Healthcare Fund directly holds 7,485,080 shares, equal to 12.1% of the class.

Do the reporting persons claim voting or dispositive power over the shares?

The cover pages show 0 sole voting and dispositive power and 7,676,697 shared voting and shared dispositive power; RA Capital is delegated sole power by the funds to vote and dispose of the shares.

Did the filers claim they intend to influence control of GH Research?

No. The certification states the securities were not acquired to change or influence control, and the filers used Schedule 13G/A consistent with a passive position.

What outstanding share count is used to calculate the percent ownership?

The percentage is based on 62,028,145 Ordinary Shares outstanding as reported in the issuer’s Form F-3 filed February 27, 2025.
Gh Research Plc

NASDAQ:GHRS

GHRS Rankings

GHRS Latest News

GHRS Latest SEC Filings

GHRS Stock Data

817.55M
42.51M
31.47%
70.41%
3.54%
Biotechnology
Healthcare
Link
Ireland
Dublin